Demographic, clinical, and MRI characteristics of patients at first line TNFi initiation. Values are n (%) unless otherwise specified.
| Characteristic | No. Patients Assessed | Radiographic axSpA, n = 263 | nr-axSpA, n = 98 | p |
|---|---|---|---|---|
| Male* | 361 | 171 (65.02) | 45 (45.92) | 0.001 |
| Age, yrs, mean ± SD | 360 | 43.93 ± 11.99 | 40.97 ± 12.94 | 0.04 |
| Symptom duration, yrs, mean ± SD | 326 | 11.71 ± 9.52 | 7.34 ± 9.30 | < 0.001 |
| Symptom duration ≤ 5 yrs* | 326 | 77 (32.91) | 51 (55.43) | < 0.001 |
| HLA-B27–positive* | 316 | 175 (78.13) | 67 (72.83) | 0.31 |
| Current or past uveitis* | 361 | 47 (17.87) | 12 (12.24) | 0.19 |
| Current or past IBD* | 361 | 36 (13.69) | 12 (12.24) | 0.72 |
| Current or past psoriasis* | 361 | 25 (9.51) | 18 (18.37) | 0.02 |
| Positive SpA family history* | 361 | 41 (15.59) | 20 (20.41) | 0.28 |
| MRI of sacroiliac* | 119 | 49 (18.6) | 70 (71.4) | < 0.001 |
| Sacroiliitis on MRI, past or present* | 119 | 40 (81.6) | 39 (59.7) | 0.003 |
| MRI of spine* | 81 | 43 (16.3) | 38 (38.8) | < 0.001 |
| MRI detection of spinal inflammation, past or present* | 81 | 20 (46.5) | 15 (39.5) | 0.52 |
↵* Percentage values refer to the number of patients with available information. Significant data are in bold face. MRI: magnetic resonance imaging; TNFi: tumor necrosis factor inhibitor; SpA: spondyloarthritis; axSpA: axial SpA; nr-axSpA; nonradiographic axSpA; IBD: inflammatory bowel disease.